Metotreksat Intramuskular untuk Terapi Psoriasis Vulgaris: Serial Kasus
DOI:
https://doi.org/10.55175/cdk.v45i8.739Kata Kunci:
Injeksi, intramuskular, metrotreksat, psoriasis vulgarisAbstrak
Metotreksat merupakan pilihan terapi psoriasis yang efektif. Laporan pemberian MTX parenteral pada psoriasis vulgaris masih jarang. Kami melaporkan 8 kasus psoriasis vulgaris dengan terapi injeksi MTX dosis inisial 10 mg/minggu dan dinaikkan menjadi 15 mg/minggu. Dalam evaluasi 8-12 minggu, terdapat perbaikan klinis yang dievaluasi menggunakan Psoriasis Activity and Severity Index (PASI), luas Body Surface Area (BSA), dan Dermatology Life Quality Index (DLQI). Bioavailabilitas MTX parenteral lebih baik dibandingkan per oral. Tidak ditemukan efek samping selama pemberian injeksi MTX.
Methotrexate (MTX) is the commonly prescribed for psoriasis. Reports on parenteral MTX for psoriasis in Indonesia are still scarce. We reported eight psoriasis patients treated with intramuscular MTX 10 mg/week increased to 15 mg/week. The clinical improvement was remarkable demonstrated with Body Surface Area (BSA), Psoriasis Activity and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) scores. Bioavailability of parenteral MTX is better than oral MTX. No adverse effect was found and the clinical improvement was good.
Unduhan
Referensi
Gudjonsson JE, Elder JT. Psoriasis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell D J, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 1st ed. New York: Mc Graw Hill; 2012. p. 197-231.
Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (metop): A 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528-37.
Gudjonsson J.E E J T. Psoriasis. In: Lowell A. Goldsmith S I K BAG, Amy S. Paller, David J. Leffell, Klaus Wolff, editor. Fitzpatrick’s dermatology in general medicine. 1st ed. New York: McGraw Hill; 2012. p. 197-231.
Carretero G, Puig L, Dehesa L, Carrascosa JM, Ribera M, Sanchez-Regana M, et al. [guidelines on the use of methotrexate in psoriasis]. Actas Dermosifiliogr. 2010;101(7):600-13.
Menting SP, Dekker PM, Limpens J, Hooft L, Spuls P I. Methotrexate dosing regimen for plaque-type psoriasis: A systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. Acta Derm Venereol. 2016;96(1):23-8.
Menter A, Korman N J, Elmets C A, Feldman S R, Gelfand J M, Gordon K B, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-85.
Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168-73.
Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the psoriasis area and severity index (pasi 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-66.
Silva MF, Fortes MR, Miot LD, Marques SA. Psoriasis: Correlation between severity index (pasi) and quality of life index (dlqi) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013;88(5):760-3.
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: A comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997-1035.
Faria JR, Aarao AR, Jimenez LM, Silva OH, Avelleira JC. Inter-rater concordance study of the pasi (psoriasis area and severity index). An Bras Dermatol. 2010;85(5):625-9.
Jacobson CC, Kimball AB. Rethinking the psoriasis area and severity index: The impact of area should be increased. Br J Dermatol. 2004;151(2):381-7.
Ihtatho D, Fadzil MH, Affandi AM, Hussein SH. Area assessment of psoriasis lesion for pasi scoring. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:3446-9.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: A european consensus. Arch Dermatol Res. 2011;303(1):1-10.
Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216(3):260-70.
Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol. 1999;11(3):226-32.
Weidmann A, Foulkes AC, Kirkham N, Reynolds NJ. Methotrexate toxicity during treatment of chronic plaque psoriasis: A case report and review of the literature. Dermatol Ther (Heidelb). 2014;4(2):145-56.
Van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010;28(5 Suppl 61):27-32.
Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 national psoriasis foundation consensus conference. J Am Acad Dermatol. 2009;60(5):824-37.
Shen S, O’Brien T, Yap L M, Prince HM, McCormack CJ. The use of methotrexate in dermatology: A review. Australas J Dermatol. 2012;53(1):1-18.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
